Close Menu

NEW YORK – The European Commission has approved pembrolizumab (Merck's Keytruda) as a standalone treatment or paired with 5-FU chemotherapy as a first-line option for patients with metastatic or unresectable, recurrent head and neck cancer if their tumors have a PD-L1 combined positive score of 1 or more. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.